VKTX · Company research
Viking Therapeutics, Inc (VKTX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
43records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks - Stocktwits | VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks Stocktwits | View source ↗ | Stocktwits | Oct 19, 2026 | neutral | 0 | 0.6 |
| Viking Therapeutics (VKTX) As SUNRISE Phase 3 Starts Is The Stock Fully Priced - Simply Wall Street | Viking Therapeutics (VKTX) As SUNRISE Phase 3 Starts Is The Stock Fully Priced Simply Wall Street | View source ↗ | Simply Wall Street | Oct 19, 2026 | neutral | 0 | 0.6 |
| Viking Therapeutics Slides as Financing Overhang and Competitive Concerns Weigh on Sentiment - Quiver Quantitative | Viking Therapeutics Slides as Financing Overhang and Competitive Concerns Weigh on Sentiment Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 16, 2026 | neutral | 0 | 0.6 |
| Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know | Viking Therapeutics (VKTX) declined 8.26% on October 16, 2026, significantly underperforming the S&P 500's 1.09% loss. The stock has fallen 6.78% over the past month, lagging the Medical sector's 2.68% gain. The company faces negative earnings forecasts with an expected EPS of -$1 for the upcoming quarter and -$4.46 for the full year, though it maintains a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bearish | -1 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Viking Therapeutics Starts Phase III Development of Obesity Pill | Viking Therapeutics announced the initiation of the SUNRISE phase III program to evaluate its oral VK2735 formulation for obesity treatment. The program consists of two studies targeting 560 adults each, with and without type 2 diabetes. Phase II results showed up to 12.2% mean weight loss at the highest dose versus 1.3% with placebo. Despite positive developments, VKTX stock declined 4.4% on the announcement day and is down 27.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.333 | 1 |
| Viking Therapeutics Starts Phase III Development of Obesity Pill | Viking Therapeutics announced the initiation of the SUNRISE phase III program to evaluate its oral VK2735 formulation for obesity treatment. The program consists of two studies targeting 560 adults each, with and without type 2 diabetes. Phase II results showed up to 12.2% mean weight loss at the highest dose versus 1.3% with placebo. Despite positive developments, VKTX stock declined 4.4% on the announcement day and is down 27.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.333 | 1 |
| Viking Therapeutics Inc (VKTX) Stock Price Target & Forecast - TradingKey | Viking Therapeutics Inc (VKTX) Stock Price Target & Forecast TradingKey | View source ↗ | TradingKey | Oct 15, 2026 | neutral | 0 | 0.6 |
| An obesity pill showed up to 12.2% mean weight loss in 13 weeks. Viking starts third-stage trials. - Stock Titan | An obesity pill showed up to 12.2% mean weight loss in 13 weeks. Viking starts third-stage trials. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| 4 High-Risk Stocks Built for Big Returns | The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize. | View source ↗ | The Motley Fool | Oct 14, 2026 | bullish | 0.571 | 1 |
| 4 High-Risk Stocks Built for Big Returns | The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize. | View source ↗ | The Motley Fool | Oct 14, 2026 | bullish | 0.571 | 1 |
| Viking Therapeutics (VKTX) Stock Dropped, So What Is Driving Attention Now? - Yahoo Finance | Viking Therapeutics (VKTX) Stock Dropped, So What Is Driving Attention Now? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| VKTX Stock Slides After-Hours On $400M Stock-And-Notes Raise After Tuesday’s Rally - Stocktwits | VKTX Stock Slides After-Hours On $400M Stock-And-Notes Raise After Tuesday’s Rally Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits | VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t - Stocktwits | VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| Novo Down 11% in a Month: How Should Investors Approach the Stock Now? | Novo Nordisk shares fell 11.1% over the past month following disappointing Capital Markets Day guidance that lacked near-term clarity. The company faces headwinds from intensifying competition with Eli Lilly's obesity drugs, lower U.S. pricing pressure, and pipeline setbacks including the failed CagriSema trial. While long-term opportunities exist in rare diseases and next-generation GLP-1 candidates, short-term investors should wait for stabilization signs, though long-term holders may maintain positions given valuation discounts and market potential. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.5 | 1 |
| Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. | Oppenheimer analyst Jay Olson raised his price target on Viking Therapeutics to $120 from $100, implying a potential quadrupling from the current $28.50 price. The bullish call is based on positive maintenance trial data for VK2735, a GLP-1 and GIP agonist drug, which increased the probability of success from 80% to 90%. Wall Street consensus projects VK2735 could generate $1.5 billion in 2030 sales rising to $6.5 billion by 2035, potentially capturing market share from Eli Lilly's tirzepatide, which is expected to reach $80 billion in total sales by 2030. | View source ↗ | The Motley Fool | Oct 12, 2026 | bullish | 0.5 | 1 |
| VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits | VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits | VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? | Viking Therapeutics is advancing its oral weight-loss drug VK2735 to Phase 3 trials, showing 12.2% weight loss in Phase 2 testing. However, the company faces significant competitive challenges from established players like Eli Lilly's Foundayo, which demonstrated better tolerability with lower discontinuation rates. While Viking's injectable formulation shows promise with potential monthly dosing differentiation, the biotech will struggle to gain market traction in an increasingly crowded obesity drug market dominated by incumbents. | View source ↗ | The Motley Fool | Oct 10, 2026 | bullish | 0.5 | 1 |
| Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider | Viking Therapeutics (VKTX) closed at $28.53, up 2.88% and outperforming the S&P 500's 0.6% gain. However, the stock has declined 13.69% over the past month. The company is expected to report an EPS of -$1 (down 23.46% YoY) with annual earnings projected at -$4.46 per share and zero revenue. Despite negative earnings outlook, VKTX holds a Zacks Rank #2 (Buy) rating with a slight 0.16% upward revision in consensus EPS projections over the past 30 days. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know | Viking Therapeutics (VKTX) declined 2.84% to $27.73, underperforming the S&P 500's 0.47% loss. The stock has fallen 12.72% over the past month, significantly trailing the Medical sector's 3.97% decline. The company is projected to report negative earnings of -$1 per share with a 23.46% year-over-year decline, and annual estimates show -$4.47 EPS with zero revenue. Despite these challenges, VKTX maintains a Zacks Rank #2 (Buy) rating with no recent changes to consensus estimates. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bearish | -1 | 1 |
| Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know | Viking Therapeutics (VKTX) declined 2.84% to $27.73, underperforming the S&P 500's 0.47% loss. The stock has fallen 12.72% over the past month, significantly trailing the Medical sector's 3.97% decline. The company is projected to report negative earnings of -$1 per share with a 23.46% year-over-year decline, and annual estimates show -$4.47 EPS with zero revenue. Despite these challenges, VKTX maintains a Zacks Rank #2 (Buy) rating with no recent changes to consensus estimates. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bearish | -1 | 1 |
| LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? | Eli Lilly's stock has declined 2.3% in three months despite strong business fundamentals, driven by valuation concerns and competition worries rather than operational deterioration. The company's GLP-1 drugs Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales, while newly launched oral pill Foundayo is gaining traction with coverage from all major PBMs. Lilly is successfully diversifying beyond GLP-1 with non-cardiometabolic revenues growing 121% in Q2, and the pipeline includes promising candidates like retatrutide. However, headwinds include pricing pressure, rising competition, and slower expected second-half growth. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? | Eli Lilly's stock has declined 2.3% in three months despite strong business fundamentals, driven by valuation concerns and competition worries rather than operational deterioration. The company's GLP-1 drugs Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales, while newly launched oral pill Foundayo is gaining traction with coverage from all major PBMs. Lilly is successfully diversifying beyond GLP-1 with non-cardiometabolic revenues growing 121% in Q2, and the pipeline includes promising candidates like retatrutide. However, headwinds include pricing pressure, rising competition, and slower expected second-half growth. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| VKTX Advances Obesity Program With New Oral Maintenance Study | Viking Therapeutics initiated a clinical study testing oral and injectable maintenance dosing regimens for VK2735, its lead obesity candidate. Earlier results showed every-other-week and monthly dosing retained approximately 90% and 85% of prior weight loss respectively. The company plans to start late-stage oral studies by year-end, though it faces intense competition from Eli Lilly and Novo Nordisk's established obesity treatments. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.333 | 1 |
| VKTX Advances Obesity Program With New Oral Maintenance Study - Yahoo Finance | VKTX Advances Obesity Program With New Oral Maintenance Study Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| VKTX Down 16% in a Month: Time to Invest or Exit the Stock? - Yahoo Finance | VKTX Down 16% in a Month: Time to Invest or Exit the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| After 21 weeks of shots, Viking will test pills to maintain weight loss. - Stock Titan | After 21 weeks of shots, Viking will test pills to maintain weight loss. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock | Eli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations. | View source ↗ | The Motley Fool | Oct 5, 2026 | neutral | 0 | 1 |
| Here Are My Top 4 Stocks to Buy in October | The article recommends four stocks for October investment: Viking Therapeutics for its unique monthly-dose GLP-1 weight loss drug candidate in a market expected to reach $200 billion by 2030; Alphabet for its dominant position in cloud computing AI services with 82% YoY growth and gaining market share; SoFi Technologies for strong revenue growth (40% YoY) and customer expansion despite recent setbacks; and MercadoLibre for its Amazon-like growth trajectory in Latin America with 50% YoY revenue growth despite margin pressures from free shipping initiatives. | View source ↗ | The Motley Fool | Oct 5, 2026 | bullish | 0.636 | 1 |
| Significant stock movers of September: Viking soars, Longeveron slides - BioSpace | Significant stock movers of September: Viking soars, Longeveron slides BioSpace | View source ↗ | BioSpace | Oct 5, 2026 | neutral | 0 | 0.6 |
| Viking Therapeutics (VKTX) On Fresh VK2735 Data And New Funding Still Looks Pricey - Simply Wall Street | Viking Therapeutics (VKTX) On Fresh VK2735 Data And New Funding Still Looks Pricey Simply Wall Street | View source ↗ | Simply Wall Street | Oct 4, 2026 | neutral | 0 | 0.6 |
| Prediction: This Stock Could Double Over the Next 5 Years | Viking Therapeutics' weight loss drug VK2735 shows strong clinical promise with potential for dual-formulation therapy (injectable followed by oral maintenance). The company raised $500 million to fund pipeline development. With the obesity drug market projected to reach $77 billion by 2030, even a small 1.4% market share could generate $1.2 billion in revenue for Viking's $4 billion market cap, suggesting significant upside potential, though clinical trial risks remain. | View source ↗ | The Motley Fool | Oct 2, 2026 | bullish | 0.5 | 1 |
| Prediction: This Stock Could Double Over the Next 5 Years | Viking Therapeutics' weight loss drug VK2735 shows strong clinical promise with potential for dual-formulation therapy (injectable followed by oral maintenance). The company raised $500 million to fund pipeline development. With the obesity drug market projected to reach $77 billion by 2030, even a small 1.4% market share could generate $1.2 billion in revenue for Viking's $4 billion market cap, suggesting significant upside potential, though clinical trial risks remain. | View source ↗ | The Motley Fool | Oct 2, 2026 | bullish | 0.5 | 1 |
| Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors | Viking Therapeutics (VKTX) stock declined 6.41% on October 1, 2026, underperforming the broader market which gained 0.2%. The company is expected to report negative EPS of -$1 for the upcoming quarter, down 23.46% year-over-year, with full-year earnings forecasted at -$4.47 per share. Despite the losses, VKTX maintains a Zacks Rank #2 (Buy) rating, though its industry ranks in the bottom 27% of all sectors. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bearish | -1 | 1 |
| Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors | Viking Therapeutics (VKTX) stock declined 6.41% on October 1, 2026, underperforming the broader market which gained 0.2%. The company is expected to report negative EPS of -$1 for the upcoming quarter, down 23.46% year-over-year, with full-year earnings forecasted at -$4.47 per share. Despite the losses, VKTX maintains a Zacks Rank #2 (Buy) rating, though its industry ranks in the bottom 27% of all sectors. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bearish | -1 | 1 |
| About $575 million came in for Viking Therapeutics, including $258.75 million in debt that can turn into shares. - Stock Titan | About $575 million came in for Viking Therapeutics, including $258.75 million in debt that can turn into shares. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes - PR Newswire | Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes PR Newswire | View source ↗ | PR Newswire | Sep 24, 2026 | neutral | 0 | 0.6 |
| VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3 - Stocktwits | VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3 Stocktwits | View source ↗ | Stocktwits | Sep 1, 2026 | neutral | 0 | 0.6 |
| Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. - The Motley Fool | Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. The Motley Fool | View source ↗ | The Motley Fool | Aug 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.